• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpaceCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech

Latest content

ShowingAll content types

Gubra: UCN2 enters the clinic with an ambitious Phase 1/2a design and an R&D Day date

Analyst Comment 2026-07-28 08:50 by Michael Friis
Gubra

Gubra: Boehringer Ingelheim initiates Phase 2 of triple agonist, triggering EUR 10m milestone

Analyst Comment 2026-07-16 07:49 by Michael Friis
Gubra

Ascelia Pharma: Market is pricing the downside, but the CRL letter and management commentary still support better scenarios

Analyst Comment 2026-07-15 08:03 by Michael Friis
Ascelia Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Ascelia Pharma: Published FDA letter raises the odds of a more demanding path for Orviglance

Analyst Comment 2026-07-14 08:20 by Michael Friis
Ascelia Pharma

GreenMobility (Investment case): H1 2026, profitability and cash returns proven, H2 to restore the growth trajectory

Research 2026-07-13 13:00 by Michael Friis, Victor Skriver
GreenMobility

Ascelia Pharma: Update on Orviglance NDA suggests clinical CRL concerns center on image reading

Analyst Comment 2026-07-13 07:45 by Michael Friis
Ascelia Pharma

GreenMobility: Presentation H1 2026 results (Recording)

Analyst Comment 2026-07-10 14:27 by Michael Friis
GreenMobility

GomSpace – Management Q&A (Recording)

Analyst Comment 2026-07-10 14:18 by Michael Friis
GomSpace

GreenMobility: H1-2026 Full report confirms preliminary figures, balance sheet and cash flow underline earnings quality

Analyst Comment 2026-07-09 08:00 by Michael Friis
GreenMobility

GreenMobility: Lowers revenue guidance but keeps EBITDA growth intact

Analyst Comment 2026-07-07 07:48 by Michael Friis
GreenMobility